CRO Phastar pens tech deal with newly bought out Medidata

InterSystems Clinical Trial
CRO Phastar pens technology deal with Medidata Solutions as the clinical trial firm is being bought out by French company Dassault Systemes. (InterSystems)

Phastar has signed up to use Medidata Solutions' trial cloud technology with an eye on boosting its work in the U.S.

Under the deal, financial details of which were not made public, trial and data science specialist Phastar will use Medidata’s so-called Rave Clinical Cloud, which the company says in a statement will allow "Phastar to design and conduct complex clinical trials and turn large volumes of data into insights.”

The CRO recently expanded its data operations teams in Kenya and the U.K. and also cut the ribbon on its second U.S. office in Boston; its partnership with Medidata will “further power its U.S. expansion,” it added. 


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

This also comes a week after Medidata Solutions was bought out by France’s Dassault Systemes in a $5.7 billion deal.

RELATED: Dassault Systemes eyes life science boost with $5.7B Medidata buy

Andrew MacGarvey, managing director at Phastar, said: “I am pleased to expand our offering following the addition of the Medidata platform to our technology solutions. Our Data Operations team delivers excellent services across the world and Medidata will allow the team to service projects more efficiently as they work within the unified platform.

“Our new Data Sciences group is developing tools and techniques to help our customers maximize the data they collect. Medidata understands that the types of data collected during clinical trials are changing and the amount of data underpinning clinical research is increasing extremely quickly. We hope to work closely with their team as our customer needs evolve over the coming years.”

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.